The estimated Net Worth of Elsas Andrea Van is at least $43.7 Milion dollars as of 25 February 2020. Elsas Van owns over 6,823 units of Aduro BioTech stock worth over $43,179,150 and over the last 7 years Elsas sold ADRO stock worth over $482,358.
Sign up
Elsas Van ADRO stock SEC Form 4 insiders trading
Elsas has made over 13 trades of the Aduro BioTech stock since 2017, according to the Form 4 filled with the SEC. Most recently Elsas sold 6,823 units of ADRO stock worth $23,949 on 25 February 2020.
The largest trade Elsas's ever made was selling 73,311 units of Aduro BioTech stock on 3 January 2020 worth over $87,240. On average, Elsas trades about 8,297 units every 47 days since 2017. As of 25 February 2020 Elsas still owns at least 438,367 units of Aduro BioTech stock.
You can see the complete history of Elsas Van stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Elsas Van's mailing address?
Elsas's mailing address filed with the SEC is KLOOSTERSTRAAT 9, , OSS, P7, 5349 AB.
Insiders trading at Aduro BioTech
Over the last 10 years, insiders at Aduro BioTech have traded over $5,295,750 worth of Aduro BioTech stock and bought 614,134 units worth $10,440,278 . The most active insiders traders include William Mariner Greenman, Stephen T Isaacs oraz Thomas W. Dubensky. On average, Aduro BioTech executives and independent directors trade stock every 11 days with the average trade being worth of $2,189,064. The most recent stock trade was executed by Stephen T Isaacs on 15 September 2020, trading 32,481 units of ADRO stock currently worth $77,630.
What does Aduro BioTech do?
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
What does Aduro BioTech's logo look like?
Complete history of Elsas Van stock trades at Aduro BioTech
Aduro BioTech executives and stock owners
Aduro BioTech executives and other stock owners filed with the SEC include:
-
William Greenman,
Independent Director -
Ross Haghighat,
Independent Director -
Eric Bjerkholt,
Chief Financial Officer -
Noopur Liffick,
IR Contact Officer -
Dolca Thomas,
Director -
Michelle Griffin,
Director -
Jerel Davis,
Director -
Srinivas Akkaraju,
Director -
Alan Glicklich,
Chief Medical Officer -
Tom Frohlich,
Chief Business Officer -
Eric Dobmeier,
President, Chief Executive Officer, Director -
Thomas W. Dubensky,
Chief Scientific Officer -
Gregory W Schafer,
Chief Operating Officer -
Natalie Sacks,
Chief Medical Officer -
Frank Mccormick,
Director -
Gerald Chan,
Director -
Stephen T Isaacs,
President and CEO -
Stephanie Monaghan O Brien,
Director -
Stephen A Sherwin,
Director -
Dirk G. Brockstedt,
Sr. VP of Research and Dev. -
Frank Karbe,
Director -
Elsas Andrea Van,
Chief Scientific Officer -
David Henry Mack,
Director -
Celeste Ferber,
SVP, GC and Secretary -
Dimitry Sa Nuyten,
Chief Medical Officer -
Jennifer Lew,
Sr. Vice President of Finance -
Venture (Vi) Investments Lt...,
10% owner -
John E. And Lois A. Rogers,
10% owner -
Keen Ltd Ultimate,
10% owner -
Blaine Templeman,
Chief Legal Officer -
James H Welch,
See Remarks -
William G Kachioff,
Interim CFO